Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Unicycive Therapeutics, Inc. (UNCY) ownership amendment reports that Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, each beneficially own 3,911,375 shares of common stock issuable upon full conversion of Series A-3, A-4 and A-5 preferred stock underlying Tranche A, B and C warrants exercisable within 60 days. Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, each report 394,884 shares on the same basis.
Each reporting person reports 9.99% of the class. The share counts assume full conversion and do not give effect to provisions barring conversion if it would result in the holder owning more than 9.99% of UNCY’s voting securities.
Key Figures
Common shares issuable upon full conversion:3,911,375 sharesCommon shares issuable upon full conversion:394,884 sharesReported percentage of class:9.99%
3 metrics
Common shares issuable upon full conversion3,911,375 sharesReported by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC; the figure does not give effect to the blocking provisions.
Common shares issuable upon full conversion394,884 sharesReported by Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Cayman, LLC; the figure does not give effect to the blocking provisions.
Reported percentage of class9.99%Reported by each reporting person; preferred-stock conversion is blocked if it would result in ownership above 9.99% of voting securities.
Key Terms
Series A-3 Convertible Preferred Stock, Tranche A Warrants, beneficially owned, blocking provisions
4 terms
Series A-3 Convertible Preferred Stocktechnical
"shares of Series A-3 Convertible Preferred Stock"
Tranche A Warrantstechnical
"underlying Tranche A Warrants exercisable within 60 days"
beneficially ownedfinancial
"Aggregate Amount Beneficially Owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
blocking provisionstechnical
"do not give effect to the blocking provisions"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many UNCY shares does Vivo report beneficially owning?
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, each report 3,911,375 shares issuable upon full conversion; Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, each report 394,884 shares on the same basis.
What limits conversion of Vivo’s UNCY preferred stock?
The preferred-stock provisions bar conversion if it would result in the holder obtaining more than 9.99% of UNCY’s voting securities. The reported common-share counts assume full conversion and do not give effect to those provisions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 5)
Unicycive Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
90466Y202
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Vivo Opportunity Fund Holdings, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,911,375.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,911,375.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,911,375.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 1,162,841 shares of common stock, par value $0.001 per share (the "Common Stock") of Unicycive Therapeutics, Inc. (the "Issuer") issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share (the "Series A-3 Preferred Stock") underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 1,057,129 shares of Common Stock issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock, par value $0.001 per share (the "Series A-4 Preferred Stock") underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 1,691,405 shares of Common Stock issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock, par value $0.001 per share (the "Series A-5 Preferred Stock") underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Vivo Opportunity, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,911,375.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,911,375.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,911,375.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 1,162,841 shares of Common Stock of the Issuer, issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 1,057,129 shares of Common Stock issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 1,691,405 shares of Common Stock issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Vivo Opportunity Cayman Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
394,884.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
394,884.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
394,884.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 117,398 shares of Common Stock of the Issuer, issuable upon conversion of 63.39492 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 106,725 shares of Common Stock issuable upon conversion of 62.96775 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 170,761 shares of Common Stock issuable upon conversion of 126.36314 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Vivo Opportunity Cayman, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
394,884.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
394,884.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
394,884.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 117,398 shares of Common Stock of the Issuer, issuable upon conversion of 63.39492 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 106,725 shares of Common Stock issuable upon conversion of 62.96775 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 170,761 shares of Common Stock issuable upon conversion of 126.36314 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Unicycive Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1975 W. El Camino Real, Suite 204, Mountain View, CA 94040
Item 2.
(a)
Name of person filing:
(i) Vivo Opportunity Fund Holdings, L.P.
(ii) Vivo Opportunity, LLC
(iii) Vivo Opportunity Cayman Fund, L.P.
(iv) Vivo Opportunity Cayman, LLC
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.
(c)
Citizenship:
(i) Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.
(ii) Vivo Opportunity, LLC is a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(iii) Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership.
(iv) Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
90466Y202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The shares held by Vivo Opportunity Fund Holdings, L.P.as of the filing date represent (i) 1,162,841 shares of Common Stock of the Issuer, issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 1,057,129 shares of Common Stock issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 1,691,405 shares of Common Stock issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The shares held by Vivo Opportunity Cayman Fund, L.P. as of the filing date represent (i) 117,398 shares of Common Stock of the Issuer, issuable upon conversion of 63.39492 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 106,725 shares of Common Stock issuable upon conversion of 62.96775 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 170,761 shares of Common Stock issuable upon conversion of 126.36314 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
(b)
Percent of class:
Vivo Opportunity Fund Holdings, L.P. 9.99%*
Vivo Opportunity, LLC 9.99%*
Vivo Opportunity Cayman Fund, L.P. 9.99%*
Vivo Opportunity Cayman, LLC 9.99%*
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Vivo Opportunity Fund Holdings, L.P. 3,911,375
Vivo Opportunity, LLC 3,911,375
Vivo Opportunity Cayman Fund, L.P. 394,884
Vivo Opportunity Cayman, LLC 394,884
(ii) Shared power to vote or to direct the vote:
Vivo Opportunity Fund Holdings, L.P. 0
Vivo Opportunity, LLC 0
Vivo Opportunity Cayman Fund, L.P. 0
Vivo Opportunity Cayman, LLC 0
(iii) Sole power to dispose or to direct the disposition of:
Vivo Opportunity Fund Holdings, L.P. 3,911,375
Vivo Opportunity, LLC 3,911,375
Vivo Opportunity Cayman Fund, L.P. 394,884
Vivo Opportunity Cayman, LLC 394,884
(iv) Shared power to dispose or to direct the disposition of:
Vivo Opportunity Fund Holdings, L.P. 0
Vivo Opportunity, LLC 0
Vivo Opportunity Cayman Fund, L.P. 0
Vivo Opportunity Cayman, LLC 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vivo Opportunity Fund Holdings, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:
11/16/2026
Vivo Opportunity, LLC
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member
Date:
11/16/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner